Angelberger Marianne, Barnikel Michaela, Fraccaroli Alessia, Tischer Johanna, Antón Sofía, Pawlikowski Alexandra, Op den Winkel Mark, Stemmler Hans Joachim, Stecher Stephanie-Susanne
Department of Medicine II, University Hospital, LMU Munich, Munich 81377, Germany.
Department of Medicine V, University Hospital, LMU Munich, Munich 81377, Germany.
Crit Care Res Pract. 2022 May 26;2022:5356413. doi: 10.1155/2022/5356413. eCollection 2022.
Percutaneous dilatational tracheostomy (PDT) has become the preferred method in several intensive care units (ICUs), but data on PDT performed in immunosuppressed and thrombocytopenic patients are scarce. This study aimed to analyze the feasibility of PDT in immunosuppressed and thrombocytopenic patients compared to conventional open surgical tracheostomy (OST).
We retrospectively analyzed the charts of patients who underwent PDT or OST between May 2017 and November 2020. Our outcomes were stoma site infections and bleeding complications.
63 patients underwent PDT, and 21 patients underwent OST. Distribution of gender ratio, age, SAPS II, time of ventilation before tracheostomy, and preexisting hematooncological diseases was comparable between the two groups. After allogeneic stem cell transplantation (alloSCT), patients were more likely to undergo PDT than OST (=0.033). The PDT cohort suffered from mucositis more frequently (=0.043). There were no significant differences in leucocyte or platelet count on the tracheostomy day. Patients with coagulation disorders and patients under immunosuppression were distributed equally among both groups. Stoma site infection was documented in five cases in PDT and eight cases in the OST group. Moderate infections were remarkably increased in the OST group. Smears were positive in six cases in the PDT group; none of these patients had local infection signs. In the OST group, smears were positive in four cases; all had signs of a stroma site infection. Postprocedural bleedings occurred in eight cases (9.5%) and were observed significantly more often in the OST group (=0.001), leading to emergency surgery in one case of the OST group.
PDT is a feasible and safe procedure in a predominantly immunosuppressed and thrombocytopenic patient cohort without an increased risk for stoma site infections or bleeding complications.
经皮扩张气管切开术(PDT)已成为多个重症监护病房(ICU)的首选方法,但关于在免疫抑制和血小板减少患者中进行PDT的数据很少。本研究旨在分析与传统开放性手术气管切开术(OST)相比,PDT在免疫抑制和血小板减少患者中的可行性。
我们回顾性分析了2017年5月至2020年11月期间接受PDT或OST的患者病历。我们的观察指标为造口部位感染和出血并发症。
63例患者接受了PDT,21例患者接受了OST。两组之间的性别比例、年龄、简化急性生理学评分II(SAPS II)、气管切开术前通气时间以及既往血液肿瘤疾病分布具有可比性。在异基因干细胞移植(alloSCT)后,患者接受PDT的可能性高于OST(P=0.033)。PDT队列中口腔炎的发生率更高(P=0.043)。气管切开当天白细胞或血小板计数无显著差异。凝血障碍患者和免疫抑制患者在两组中的分布相同。PDT组有5例记录到造口部位感染,OST组有8例。OST组中度感染明显增加。PDT组6例涂片呈阳性;这些患者均无局部感染迹象。OST组4例涂片呈阳性;所有患者均有造口部位感染迹象。术后出血发生8例(9.5%),在OST组中观察到的频率明显更高(P=0.001),导致OST组1例患者接受急诊手术。
在以免疫抑制和血小板减少为主的患者队列中,PDT是一种可行且安全的手术,造口部位感染或出血并发症风险没有增加。